Swiss medical technology company, Regen Lab, announced today a new collaboration agreement with the Moroccan Ministries of Health and Industry aiming to boost regenerative medicine in Morocco and Africa.
Regenerative medicine is a branch of medical research that aims to substitute tissue or organs that have been damaged by disease or trauma.
The collaboration between Regen Lab and the two Moroccan ministries also includes a number of international companies and organizations, including the Dassault Systemes group (3DS), Baylor College of Medicine (Texas, USA), and the Moroccan Therapeutic Society (SOTHEMA).
The partnership aims to establish a fully integrated global operational structure dedicated to boosting the adoption of regenerative medicine in Morocco and across Africa.
To boost the adoption of regenerative medicine, the collaboration will focus on developing international regulatory standards that account for patient diversity, ensuring that the benefits of regenerative medicine are accessible to individuals from diverse backgrounds.
The collaboration will also conduct clinical research on diseases with high mortality rates, such as heart disease and cancer. Through these studies, the partners hope to identify innovative solutions and contribute to improving patient outcomes.
The initiative will also introduce an integrated platform called “InSiDDe,” designed to meet the high standards of GLP (Good Laboratory Practice) and be registered with the Federal Drug Agency (FDA) – the US health watchdog. The platform will enable the development of accessible medicines and streamline the regulatory process for new therapies.
Read also:Minister: Moroccan Hospitals have a Shortage of Doctors and Nurses
In addition, the collaboration plans to integrate digital technologies into clinical trials, using “in silico clinical trials” to enhance treatment effectiveness assessment and capture the diverse characteristics of patient populations.
Another important aspect of the partnership is the training of medical staff in cutting-edge technologies, ensuring that healthcare professionals are equipped with the necessary expertise to deliver advanced regenerative therapies.
The partnership will also support the development of clinical research in Morocco through collaborations with university hospitals. As part of this effort, plans are underway to establish the first clinical research hospital in compliance with US standards, reinforcing Morocco’s position as a hub for groundbreaking medical research.
Khalid Ait Taleb, Minister of Health and Social Protection, expressed his pride in the agreement, stating: “This partnership represents a tremendous lever to accelerate innovation in numerous therapeutic areas for the benefit of Moroccan public health, and ultimately to create a solid biotechnology industry on our territory.”
Antoine Turzi, CEO of Regen Lab Group, added: “Regen Lab is honored to be part of this ecosystem of prestigious public and private players, and we are proud to be able to bring our expertise in regenerative medicine to the Moroccan public health authorities.”
“The aim of this high-quality scientific collaboration is to produce and market new medical technologies for the benefit of Moroccan and, more broadly, African patients,” he explained.
© Morocco World News. All Rights Reserved. This material may not be published, rewritten or redistributed without permission.
Swiss medical technology company, Regen Lab, announced today a new collaboration agreement with the Moroccan Ministries of Health and Industry aiming to boost regenerative medicine in Morocco and Africa.
Regenerative medicine is a branch of medical research that aims to substitute tissue or organs that have been damaged by disease or trauma.
The collaboration between Regen Lab and the two Moroccan ministries also includes a number of international companies and organizations, including the Dassault Systemes group (3DS), Baylor College of Medicine (Texas, USA), and the Moroccan Therapeutic Society (SOTHEMA).
The partnership aims to establish a fully integrated global operational structure dedicated to boosting the adoption of regenerative medicine in Morocco and across Africa.
To boost the adoption of regenerative medicine, the collaboration will focus on developing international regulatory standards that account for patient diversity, ensuring that the benefits of regenerative medicine are accessible to individuals from diverse backgrounds.
The collaboration will also conduct clinical research on diseases with high mortality rates, such as heart disease and cancer. Through these studies, the partners hope to identify innovative solutions and contribute to improving patient outcomes.
The initiative will also introduce an integrated platform called “InSiDDe,” designed to meet the high standards of GLP (Good Laboratory Practice) and be registered with the Federal Drug Agency (FDA) – the US health watchdog. The platform will enable the development of accessible medicines and streamline the regulatory process for new therapies.
Read also:Minister: Moroccan Hospitals have a Shortage of Doctors and Nurses
In addition, the collaboration plans to integrate digital technologies into clinical trials, using “in silico clinical trials” to enhance treatment effectiveness assessment and capture the diverse characteristics of patient populations.
Another important aspect of the partnership is the training of medical staff in cutting-edge technologies, ensuring that healthcare professionals are equipped with the necessary expertise to deliver advanced regenerative therapies.
The partnership will also support the development of clinical research in Morocco through collaborations with university hospitals. As part of this effort, plans are underway to establish the first clinical research hospital in compliance with US standards, reinforcing Morocco’s position as a hub for groundbreaking medical research.
Khalid Ait Taleb, Minister of Health and Social Protection, expressed his pride in the agreement, stating: “This partnership represents a tremendous lever to accelerate innovation in numerous therapeutic areas for the benefit of Moroccan public health, and ultimately to create a solid biotechnology industry on our territory.”
Antoine Turzi, CEO of Regen Lab Group, added: “Regen Lab is honored to be part of this ecosystem of prestigious public and private players, and we are proud to be able to bring our expertise in regenerative medicine to the Moroccan public health authorities.”
“The aim of this high-quality scientific collaboration is to produce and market new medical technologies for the benefit of Moroccan and, more broadly, African patients,” he explained.
© Morocco World News. All Rights Reserved. This material may not be published, rewritten or redistributed without permission.
Swiss medical technology company, Regen Lab, announced today a new collaboration agreement with the Moroccan Ministries of Health and Industry aiming to boost regenerative medicine in Morocco and Africa.
Regenerative medicine is a branch of medical research that aims to substitute tissue or organs that have been damaged by disease or trauma.
The collaboration between Regen Lab and the two Moroccan ministries also includes a number of international companies and organizations, including the Dassault Systemes group (3DS), Baylor College of Medicine (Texas, USA), and the Moroccan Therapeutic Society (SOTHEMA).
The partnership aims to establish a fully integrated global operational structure dedicated to boosting the adoption of regenerative medicine in Morocco and across Africa.
To boost the adoption of regenerative medicine, the collaboration will focus on developing international regulatory standards that account for patient diversity, ensuring that the benefits of regenerative medicine are accessible to individuals from diverse backgrounds.
The collaboration will also conduct clinical research on diseases with high mortality rates, such as heart disease and cancer. Through these studies, the partners hope to identify innovative solutions and contribute to improving patient outcomes.
The initiative will also introduce an integrated platform called “InSiDDe,” designed to meet the high standards of GLP (Good Laboratory Practice) and be registered with the Federal Drug Agency (FDA) – the US health watchdog. The platform will enable the development of accessible medicines and streamline the regulatory process for new therapies.
In addition, the collaboration plans to integrate digital technologies into clinical trials, using “in silico clinical trials” to enhance treatment effectiveness assessment and capture the diverse characteristics of patient populations.
Another important aspect of the partnership is the training of medical staff in cutting-edge technologies, ensuring that healthcare professionals are equipped with the necessary expertise to deliver advanced regenerative therapies.
The partnership will also support the development of clinical research in Morocco through collaborations with university hospitals. As part of this effort, plans are underway to establish the first clinical research hospital in compliance with US standards, reinforcing Morocco’s position as a hub for groundbreaking medical research.
Khalid Ait Taleb, Minister of Health and Social Protection, expressed his pride in the agreement, stating: “This partnership represents a tremendous lever to accelerate innovation in numerous therapeutic areas for the benefit of Moroccan public health, and ultimately to create a solid biotechnology industry on our territory.”
Antoine Turzi, CEO of Regen Lab Group, added: “Regen Lab is honored to be part of this ecosystem of prestigious public and private players, and we are proud to be able to bring our expertise in regenerative medicine to the Moroccan public health authorities.”
“The aim of this high-quality scientific collaboration is to produce and market new medical technologies for the benefit of Moroccan and, more broadly, African patients,” he explained.
